Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization

Alveolar macrophages are the initial phagocytic cells that encounter foreign material and particulates deposited in the terminal airways. We have examined a mechanism by which these cells, after phagocytic challenge, may control or amplify the inflammatory response in lung parenchyma. Normal human a...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 65; no. 2; pp. 268 - 276
Main Authors Merrill, W W, Naegel, G P, Matthay, R A, Reynolds, H Y
Format Journal Article
LanguageEnglish
Published United States 01.02.1980
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Alveolar macrophages are the initial phagocytic cells that encounter foreign material and particulates deposited in the terminal airways. We have examined a mechanism by which these cells, after phagocytic challenge, may control or amplify the inflammatory response in lung parenchyma. Normal human alveolar macrophages (AM) were studied from eight subjects. With in vitro culture, AM produced and released two substances into culture media which have potent chemoattractant activity for blood polymorphonuclear granulocytes (PMN) and negligible activity for mononuclear cells. Release of these factors is maximally stimulated by aggregated human immunoglobulin (Ig)G or zymosan particles; however, simple adhesion of the macrophages to plastic surfaces is also sufficient to stimulate release of these chemotactic substances. The larger substance (10,000 daltons) is immunologically distinct from C5a and interacts with a different PMN membrane receptor than that known to exist for formyl-methionyl-leucyl-phenylalanine. Its chemotactic activity is sensitive to the enzymatic effect of trypsin. Although producing a single elution peak on gelfiltration chromatography, electrofocusing in polyacrylamide gels yielded five peaks of radioactivity. Chemotactic activity was localized to a fraction with a pI = 5.0. The smaller molecular weight substance has been less well characterized. Thus, the human AM can produce at least two factors which attract PMN and this capability may augment the local inflammatory response in the lung.
AbstractList Alveolar macrophages are the initial phagocytic cells that encounter foreign material and particulates deposited in the terminal airways. We have examined a mechanism by which these cells, after phagocytic challenge, may control or amplify the inflammatory response in lung parenchyma. Normal human alveolar macrophages (AM) were studied from eight subjects. With in vitro culture, AM produced and released two substances into culture media which have potent chemoattractant activity for blood polymorphonuclear granulocytes (PMN) and negligible activity for mononuclear cells. Release of these factors is maximally stimulated by aggregated human immunoglobulin (Ig)G or zymosan particles; however, simple adhesion of the macrophages to plastic surfaces is also sufficient to stimulate release of these chemotactic substances. The larger substance (10,000 daltons) is immunologically distinct from C5a and interacts with a different PMN membrane receptor than that known to exist for formyl-methionyl-leucyl-phenylalanine. Its chemotactic activity is sensitive to the enzymatic effect of trypsin. Although producing a single elution peak on gelfiltration chromatography, electrofocusing in polyacrylamide gels yielded five peaks of radioactivity. Chemotactic activity was localized to a fraction with a pI = 5.0. The smaller molecular weight substance has been less well characterized. Thus, the human AM can produce at least two factors which attract PMN and this capability may augment the local inflammatory response in the lung.Alveolar macrophages are the initial phagocytic cells that encounter foreign material and particulates deposited in the terminal airways. We have examined a mechanism by which these cells, after phagocytic challenge, may control or amplify the inflammatory response in lung parenchyma. Normal human alveolar macrophages (AM) were studied from eight subjects. With in vitro culture, AM produced and released two substances into culture media which have potent chemoattractant activity for blood polymorphonuclear granulocytes (PMN) and negligible activity for mononuclear cells. Release of these factors is maximally stimulated by aggregated human immunoglobulin (Ig)G or zymosan particles; however, simple adhesion of the macrophages to plastic surfaces is also sufficient to stimulate release of these chemotactic substances. The larger substance (10,000 daltons) is immunologically distinct from C5a and interacts with a different PMN membrane receptor than that known to exist for formyl-methionyl-leucyl-phenylalanine. Its chemotactic activity is sensitive to the enzymatic effect of trypsin. Although producing a single elution peak on gelfiltration chromatography, electrofocusing in polyacrylamide gels yielded five peaks of radioactivity. Chemotactic activity was localized to a fraction with a pI = 5.0. The smaller molecular weight substance has been less well characterized. Thus, the human AM can produce at least two factors which attract PMN and this capability may augment the local inflammatory response in the lung.
Alveolar macrophages are the initial phagocytic cells that encounter foreign material and particulates deposited in the terminal airways. We have examined a mechanism by which these cells, after phagocytic challenge, may control or amplify the inflammatory response in lung parenchyma. Normal human alveolar macrophages (AM) were studied from eight subjects. With in vitro culture, AM produced and released two substances into culture media which have potent chemoattractant activity for blood polymorphonuclear granulocytes (PMN) and negligible activity for mononuclear cells. Release of these factors is maximally stimulated by aggregated human immunoglobulin (Ig)G or zymosan particles; however, simple adhesion of the macrophages to plastic surfaces is also sufficient to stimulate release of these chemotactic substances. The larger substance (10,000 daltons) is immunologically distinct from C5a and interacts with a different PMN membrane receptor than that known to exist for formyl-methionyl-leucyl-phenylalanine. Its chemotactic activity is sensitive to the enzymatic effect of trypsin. Although producing a single elution peak on gelfiltration chromatography, electrofocusing in polyacrylamide gels yielded five peaks of radioactivity. Chemotactic activity was localized to a fraction with a pI = 5.0. The smaller molecular weight substance has been less well characterized. Thus, the human AM can produce at least two factors which attract PMN and this capability may augment the local inflammatory response in the lung.
Author Naegel, G P
Reynolds, H Y
Merrill, W W
Matthay, R A
Author_xml – sequence: 1
  givenname: W W
  surname: Merrill
  fullname: Merrill, W W
– sequence: 2
  givenname: G P
  surname: Naegel
  fullname: Naegel, G P
– sequence: 3
  givenname: R A
  surname: Matthay
  fullname: Matthay, R A
– sequence: 4
  givenname: H Y
  surname: Reynolds
  fullname: Reynolds, H Y
BackLink https://www.ncbi.nlm.nih.gov/pubmed/7356678$$D View this record in MEDLINE/PubMed
BookMark eNplkUtPHDEQhH1YRHjkkB8QySckDhNsjx-zkXJAq0A2QuICZ6vXY7NOPPbEnl2J_HoMbFCAU6tV9VVL1YdoFlO0CH2i5Aulip39XCwpmUvZzdABIYw2c9V2H9BhKb8IoZwLvo_2VSukVN0BCudha1OAjAcwOY1ruLNNb7Pf2h6btR3SBGbyBrs6Uv6Kf_to615wcthHvPVTTnjMqd9UW4oYYo9HyJOHUHnIFatpf-FRPEZ7DkKxH3fzCN1efL9Z_Giuri-Xi_OrxrCOd42DjighXMsUrFbKSeKk6Kjl1CkrGRNAKTOtoXNlBGOSgwEQSijWOc44bY_Qt-fccbMabG9snDIEPWY_QL7XCbx-rUS_1ndpq1tFW9lW_mTH5_RnY8ukB1-MDQGiTZuiFa_9EsGq8fP_h14u7Oqt-tmzXqstJVunjZ-eqqhnfdCU6Mef6ZefVeL0DfEv8733Ae2ImtY
CitedBy_id crossref_primary_10_1111_j_1365_2222_1991_tb00798_x
crossref_primary_10_1016_0041_008X_82_90057_6
crossref_primary_10_3109_tcic_7_1_34_38
crossref_primary_10_1111_j_1749_6632_1991_tb17015_x
crossref_primary_10_1016_S0025_7125_16_31517_6
crossref_primary_10_1164_ajrccm_136_4_811
crossref_primary_10_1007_BF02713886
crossref_primary_10_1097_00000441_198605000_00013
crossref_primary_10_1007_BF01964115
crossref_primary_10_3109_01902148609061491
crossref_primary_10_1016_S0272_5231_21_00164_7
crossref_primary_10_1016_S1047_9651_18_30393_0
crossref_primary_10_1016_0090_1229_87_90069_9
crossref_primary_10_3109_10408369009105897
crossref_primary_10_1016_0090_1229_83_90065_X
crossref_primary_10_1016_0008_8749_80_90219_1
crossref_primary_10_3389_fimmu_2015_00278
crossref_primary_10_1111_j_1574_6968_1990_tb13834_x
crossref_primary_10_1007_BF01982632
crossref_primary_10_1016_0002_9343_81_90577_5
crossref_primary_10_1165_ajrcmb_27_1_f243
crossref_primary_10_1016_0165_2427_85_90039_X
crossref_primary_10_1111_j_1530_0277_1995_tb01465_x
crossref_primary_10_1016_0006_291X_87_90432_3
crossref_primary_10_1007_BF02713638
crossref_primary_10_1002__SICI_1097_4652_199612_169_3_429__AID_JCP3_3_0_CO_2_Q
crossref_primary_10_1164_ajrccm_138_6_1464
crossref_primary_10_1016_0090_6980_91_90101_K
crossref_primary_10_1016_S0272_5231_21_01032_7
crossref_primary_10_1021_acsbiomaterials_8b00579
crossref_primary_10_3109_01902148409087907
crossref_primary_10_1080_15287398509530791
crossref_primary_10_1016_S0960_5428_06_80037_9
crossref_primary_10_1016_S0300_2896_15_31560_X
crossref_primary_10_1056_NEJM198401193100304
crossref_primary_10_1016_0090_1229_87_90158_9
crossref_primary_10_1164_ajrccm_142_1_57
crossref_primary_10_1002_ddr_430100406
crossref_primary_10_1164_ajrccm_141_3_683
crossref_primary_10_1378_chest_95_5_1021
crossref_primary_10_4049_jimmunol_1801485
crossref_primary_10_1016_0738_081X_86_90031_3
crossref_primary_10_1002_jat_2550080602
crossref_primary_10_1371_journal_pone_0247125
crossref_primary_10_1378_chest_80_1_Supplement_3S
crossref_primary_10_1111_j_1476_5381_1989_tb12638_x
crossref_primary_10_1016_S0022_3476_86_80761_2
crossref_primary_10_1016_0011_5029_85_90010_0
crossref_primary_10_1016_S0300_2896_15_31776_2
crossref_primary_10_1378_chest_91_1_44
crossref_primary_10_1097_00063198_200205000_00002
crossref_primary_10_1164_ajrccm_148_6_Pt_1_1671
crossref_primary_10_1378_chest_91_1_118
crossref_primary_10_1016_S0003_4975_10_61044_2
crossref_primary_10_1016_0002_9343_84_90242_0
crossref_primary_10_1164_ajrccm_139_1_39
crossref_primary_10_3109_01902148409069668
crossref_primary_10_1016_S0889_8561_22_00270_3
crossref_primary_10_1164_ajrccm_136_2_288
crossref_primary_10_1016_0014_2999_86_90337_7
crossref_primary_10_1016_0002_9343_90_90256_D
crossref_primary_10_1016_S0006_291X_88_80711_3
crossref_primary_10_1111_j_1749_6632_1985_tb20814_x
crossref_primary_10_1164_rccm_200406_788PP
crossref_primary_10_1007_BF02719671
crossref_primary_10_1007_BF02028296
crossref_primary_10_1016_S0272_5231_21_00185_4
crossref_primary_10_3109_01902148609058286
crossref_primary_10_1016_0041_008X_86_90262_0
crossref_primary_10_1016_0167_5699_81_90093_1
crossref_primary_10_1136_mp_48_4_M210
crossref_primary_10_1164_ajrccm_139_1_22
crossref_primary_10_3109_01902148809115121
crossref_primary_10_1016_0300_483X_81_90102_5
crossref_primary_10_1016_S0272_5231_21_01041_8
crossref_primary_10_1111_j_1749_6632_1996_tb32565_x
crossref_primary_10_1152_ajplung_1998_275_4_L687
crossref_primary_10_1007_BF01966691
crossref_primary_10_1164_ajrccm_138_4_921
crossref_primary_10_1097_00000441_198902000_00005
crossref_primary_10_1152_ajplung_1998_275_1_L87
crossref_primary_10_1152_ajplung_00405_2003
crossref_primary_10_1378_chest_94_3_521
crossref_primary_10_1016_S0021_9258_18_92996_0
crossref_primary_10_1056_NEJM198310133091502
crossref_primary_10_1378_chest_83_5_Supplement_1S_a
crossref_primary_10_1097_00000441_198812000_00003
crossref_primary_10_1002_bio_1170080305
crossref_primary_10_1164_ajrccm_145_2_Pt_2_S27
crossref_primary_10_1016_S0002_9440_10_65702_1
crossref_primary_10_1164_rccm_201307_1317OE
crossref_primary_10_3109_01902148009069652
crossref_primary_10_1016_0165_2427_91_90022_5
crossref_primary_10_1016_S0889_8561_22_00116_3
crossref_primary_10_1136_thx_37_11_803
crossref_primary_10_1111_j_1365_2222_1994_tb00247_x
crossref_primary_10_1164_ajrccm_137_1_38
crossref_primary_10_1016_0091_6749_89_90005_5
crossref_primary_10_1097_00003246_199904000_00008
crossref_primary_10_3109_01902149009087877
crossref_primary_10_1007_BF00916297
crossref_primary_10_1016_0011_5029_87_90010_1
crossref_primary_10_1016_0952_3278_89_90188_9
crossref_primary_10_1016_0041_008X_86_90417_5
crossref_primary_10_1016_0300_483X_85_90114_3
crossref_primary_10_1016_S0300_2896_15_31925_6
crossref_primary_10_1164_ajrccm_139_2_373
crossref_primary_10_1007_BF02116375
crossref_primary_10_3109_07357909309046949
crossref_primary_10_1016_S0033_8389_22_01118_6
crossref_primary_10_3109_01902149109062879
crossref_primary_10_4049_jimmunol_175_9_5567
crossref_primary_10_1016_S0012_3692_16_57764_2
crossref_primary_10_1164_ajrccm_140_6_1595
crossref_primary_10_4049_jimmunol_162_10_6200
crossref_primary_10_1016_S0272_5231_21_00170_2
crossref_primary_10_3109_01902148809087821
crossref_primary_10_1164_ajrccm_145_1_85
crossref_primary_10_1016_0014_4827_92_90358_F
crossref_primary_10_1136_thx_40_5_321
crossref_primary_10_1016_S0272_5231_21_00132_5
crossref_primary_10_3109_01902148809087827
crossref_primary_10_1046_j_1440_1746_1999_01880_x
crossref_primary_10_1124_jpet_109_163253
crossref_primary_10_3109_10408448909037474
crossref_primary_10_1111_j_1348_0421_1990_tb01003_x
crossref_primary_10_3109_01902148309061522
crossref_primary_10_1111_j_1365_2222_1990_tb03138_x
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1172/JCI109668
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 276
ExternalDocumentID PMC371363
7356678
10_1172_JCI109668
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
Comparative Study
GroupedDBID ---
-~X
.55
.GJ
29K
2WC
3O-
53G
5GY
5RE
8F7
AAWTL
AAYXX
ABOCM
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFFNX
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FRP
GROUPED_DOAJ
GX1
HYE
H~9
IAO
IEA
IHR
INH
IOF
IPO
J5H
KQ8
L7B
M1P
MVM
OK1
OVT
P2P
P6G
RPM
TEORI
TR2
TVE
VH1
VVN
W2D
WH7
WOQ
WOW
X7M
YOC
ZGI
ZXP
ZY1
.XZ
08G
08P
354
36B
3V.
5RS
7RV
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAKAS
AAYOK
ABPMR
ABUWG
ADZCM
AFCHL
AFKRA
ASPBG
AVWKF
AZFZN
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
EBD
ECM
EIF
EMOBN
EX3
FEDTE
FYUFA
HCIFZ
HMCUK
HVGLF
IHW
INR
IOV
ISR
ITC
LK8
M0L
M5~
M7P
N4W
NAPCQ
NPM
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OHT
OVD
OVIDX
PKN
PQQKQ
PROAC
PSQYO
Q2X
S0X
SJFOW
SV3
UHU
UKHRP
XSB
YFH
YHG
YKV
~H1
7X8
5PM
ID FETCH-LOGICAL-c2848-fa80755f327abb7f60f6581e41f7e6225a112c3c197c52264acaa575728f42413
ISSN 0021-9738
IngestDate Thu Aug 21 18:13:04 EDT 2025
Fri Jul 11 07:29:54 EDT 2025
Wed Feb 19 01:03:51 EST 2025
Tue Jul 01 01:42:52 EDT 2025
Thu Apr 24 22:54:07 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2848-fa80755f327abb7f60f6581e41f7e6225a112c3c197c52264acaa575728f42413
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink http://www.jci.org/articles/view/109668/files/pdf
PMID 7356678
PQID 74966052
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_371363
proquest_miscellaneous_74966052
pubmed_primary_7356678
crossref_citationtrail_10_1172_JCI109668
crossref_primary_10_1172_JCI109668
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 19800201
PublicationDateYYYYMMDD 1980-02-01
PublicationDate_xml – month: 2
  year: 1980
  text: 19800201
  day: 1
PublicationDecade 1980
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of clinical investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 1980
References 641351 - J Immunol. 1978 Apr;120(4):1326-32
807240 - Biochemistry. 1975 Jul;14(13):2853-60
14113111 - J Exp Med. 1964 Jan 1;119:167-76
4568301 - J Exp Med. 1973 Feb 1;137(2):387-410
619716 - Am Rev Respir Dis. 1978 Jan;117(1):15-23
807599 - J Clin Invest. 1975 Aug;56(2):376-85
14450081 - Nature. 1962 May 5;194:495-6
334799 - J Clin Invest. 1977 Dec;60(6):1280-8
13718021 - J Immunol. 1960 Aug;85:163-71
320925 - Am Rev Respir Dis. 1977 Mar;115(3):479-514
1088938 - Clin Immunol Immunopathol. 1975 Jan;3(3):334-46
4853956 - J Clin Invest. 1974 Sep;54(3):519-28
140184 - J Clin Invest. 1977 May;59(5):951-8
4412011 - J Lab Clin Med. 1974 Oct;84(4):559-73
4179068 - Scand J Clin Lab Invest Suppl. 1968;97:77-89
830662 - J Clin Invest. 1977 Jan;59(1):179-83
401834 - J Clin Invest. 1977 Feb;59(2):273-81
4132993 - J Exp Med. 1974 May 1;139(5):1175-88
13554587 - Proc Soc Exp Biol Med. 1958 May;98(1):188-92
582028 - Chest. 1979 Feb;75(2 Suppl):239-42
4996883 - J Clin Invest. 1971 Jul;50(7):1390-8
178186 - Am J Pathol. 1976 May;83(2):396-418
789778 - J Immunol Methods. 1976;13(2):191-7
1262785 - J Exp Med. 1976 May 1;143(5):1154-69
4712920 - J Immunol. 1973 Jun;110(6):1455-63
106197 - Lipids. 1979 Feb;14(2):181-93
14112262 - J Exp Med. 1963 Dec 1;118:1009-20
References_xml – reference: 4132993 - J Exp Med. 1974 May 1;139(5):1175-88
– reference: 1088938 - Clin Immunol Immunopathol. 1975 Jan;3(3):334-46
– reference: 807599 - J Clin Invest. 1975 Aug;56(2):376-85
– reference: 140184 - J Clin Invest. 1977 May;59(5):951-8
– reference: 830662 - J Clin Invest. 1977 Jan;59(1):179-83
– reference: 4412011 - J Lab Clin Med. 1974 Oct;84(4):559-73
– reference: 13718021 - J Immunol. 1960 Aug;85:163-71
– reference: 334799 - J Clin Invest. 1977 Dec;60(6):1280-8
– reference: 178186 - Am J Pathol. 1976 May;83(2):396-418
– reference: 1262785 - J Exp Med. 1976 May 1;143(5):1154-69
– reference: 320925 - Am Rev Respir Dis. 1977 Mar;115(3):479-514
– reference: 4996883 - J Clin Invest. 1971 Jul;50(7):1390-8
– reference: 789778 - J Immunol Methods. 1976;13(2):191-7
– reference: 4853956 - J Clin Invest. 1974 Sep;54(3):519-28
– reference: 106197 - Lipids. 1979 Feb;14(2):181-93
– reference: 14450081 - Nature. 1962 May 5;194:495-6
– reference: 641351 - J Immunol. 1978 Apr;120(4):1326-32
– reference: 582028 - Chest. 1979 Feb;75(2 Suppl):239-42
– reference: 807240 - Biochemistry. 1975 Jul;14(13):2853-60
– reference: 4568301 - J Exp Med. 1973 Feb 1;137(2):387-410
– reference: 14113111 - J Exp Med. 1964 Jan 1;119:167-76
– reference: 4179068 - Scand J Clin Lab Invest Suppl. 1968;97:77-89
– reference: 619716 - Am Rev Respir Dis. 1978 Jan;117(1):15-23
– reference: 13554587 - Proc Soc Exp Biol Med. 1958 May;98(1):188-92
– reference: 14112262 - J Exp Med. 1963 Dec 1;118:1009-20
– reference: 4712920 - J Immunol. 1973 Jun;110(6):1455-63
– reference: 401834 - J Clin Invest. 1977 Feb;59(2):273-81
SSID ssj0014454
Score 1.4335387
Snippet Alveolar macrophages are the initial phagocytic cells that encounter foreign material and particulates deposited in the terminal airways. We have examined a...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 268
SubjectTerms Cells, Cultured
Chemotactic Factors - biosynthesis
Chemotactic Factors - pharmacology
Female
Granulocytes - drug effects
Humans
Immunoglobulin G - administration & dosage
In Vitro Techniques
Kinetics
Leukocytes - drug effects
Macrophages - metabolism
Male
Molecular Weight
Pulmonary Alveoli - metabolism
Smoking - physiopathology
Zymosan - pharmacology
Title Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization
URI https://www.ncbi.nlm.nih.gov/pubmed/7356678
https://www.proquest.com/docview/74966052
https://pubmed.ncbi.nlm.nih.gov/PMC371363
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2MvY91Wln1VjD0MgjZ_KFbct1Ja0q7JYCQsb0a2ZJous0eXBNa_vneSLCdNYR8vJtiOFPz75XTn0_2OkPehkjmQN2ChTgXj_SJgsMoVLI-DSMECmxemx9JwlAwm_Gzam7byBKa6ZJF_LK7vrCv5H1ThHOCKVbL_gKwfFE7AZ8AXjoAwHP8K48P5SmNo2v0hsRPXBdgGpmDiFXiRAAagYEqgXFMdDP6_g1NphJmNUkR3NVtc1bhHSy1dy3CUDcCZUDbEazlft_Bdtuxa82V9feWsle1o8_tDVH-06Y1vXf9OZyQxXW_ey7dFZqb9uLTAt69Zv-rfVT1XhnIDt2IoW7oH-Ad-10dTORCyVFg1l8b62k4RjmXRuim17Xa2TbxAydizo9MQoi97z6aM9uhLdjI5P8_Gx9PxffIggvjBxNqnn316ifOek-e2P8hJTsHQn_zAm47KVvRxexPtmlcyfkIeOwjooeXGLrmnq6fk4dBtmHhG5g1F6DZF6BpFqKXIAW0IQuuSzipqCEJbglAgCHUEobcJ8pxMTo7HRwPmGmywArySPislSlH3yjgSMs9FmQQlOKSh5mEpdAKWXoI3XsTwdxUF-ulcFlKCfy-ifskxIbtHdqq60i8ITUWg0LZjnpXDMgJ-d5lqcEZFqnQZqA750DzNrHDq89gEZZ6ZKFREmX_wHfLO3_rTSq7cddN-A0kGBhGzXLLS9fJXJjgKzvaiDtmzAPlBRAyxi4CvJhvI-euotL55pZpdGMX1WIRxEr_845yvyCNDfLPd6TXZWVwt9RtwWhf5W0PAG9nynT8
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alveolar+macrophage-derived+chemotactic+factor%3A+kinetics+of+in+vitro+production+and+partial+characterization&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Merrill%2C+W+W&rft.au=Naegel%2C+G+P&rft.au=Matthay%2C+R+A&rft.au=Reynolds%2C+H+Y&rft.date=1980-02-01&rft.issn=0021-9738&rft.volume=65&rft.issue=2&rft.spage=268&rft_id=info:doi/10.1172%2FJCI109668&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon